Latest
Swiss Study Suggests Antidepressant May Help Treat Aggressive Brain Tumor
A new study conducted by Swiss scientists has found that a low-cost antidepressant drug may offer a promising treatment for glioblastoma, an aggressive and currently incurable brain tumor. Glioblastoma, which is known for its rapid growth, typically leads to death within 12 to 18 months of diagnosis, with limited treatment options available.
The study, led by researchers from University Hospital Zurich (USZ), explored the effectiveness of 132 drugs on glioblastoma cancer tissue obtained from patients who had recently undergone surgery. The primary goal was to identify medications capable of crossing the blood-brain barrier, a cellular layer that protects the central nervous system and makes it difficult for drugs to reach brain tumors.
Among the drugs tested, the antidepressant vortioxetine showed the most promise. According to the findings published in Nature Medicine, vortioxetine was “exceptionally consistent” in its performance, proving effective in 66.7% of the cancer cell samples.
Dr. Michael Weller, co-author of the study and head of USZ’s neurology department, highlighted vortioxetine’s potential as a cost-effective and safe option, saying, “The advantage of vortioxetine is that it is safe and very cost-effective.” The next step will be clinical trials to assess the drug’s effectiveness in human patients. In one trial, patients will receive vortioxetine in addition to standard treatments such as surgery, chemotherapy, and radiation. Another trial will involve a more personalized treatment approach.
Currently sold under the brand name Brintellix in the European Union by Danish drugmaker Lundbeck, vortioxetine is approved for treating major depression in the EU, Switzerland, the UK, and the US. If the trials prove successful, the antidepressant could quickly be integrated into standard therapy for glioblastoma, bypassing lengthy approval procedures.
The findings are part of a growing body of research suggesting that antidepressants may play a role in fighting brain cancer. A 2021 study in the US indicated that fluoxetine, commonly known as Prozac, may help target glioblastoma. The USZ study also found that fluoxetine, paroxetine, and brexpiprazole showed some effectiveness, though vortioxetine was the standout candidate.
However, experts caution that despite the early promise of these studies, more research is needed. A Swedish study published earlier this year found that patients with high-grade brain tumors, such as glioblastoma, had poorer survival rates when taking selective serotonin reuptake inhibitors (SSRIs), a class of drugs that includes vortioxetine and fluoxetine.
The results of upcoming clinical trials will determine whether vortioxetine and other antidepressants can meaningfully improve outcomes for brain cancer patients.
Latest
Flash Floods Devastate Thai Elephant Sanctuary, Killing Two Elephants and Forcing Evacuations
Latest
Severe Drought Causes Record Low Water Levels in Brazil’s Negro River
Latest
Oxford Scientists Develop First Ovarian Cancer Vaccine in Groundbreaking Research
-
Business8 months ago
Saudi Arabia’s Model for Sustainable Aviation Practices
-
Business8 months ago
Recent Developments in Small Business Taxes
-
Politics8 months ago
Who was Ebrahim Raisi and his status in Iranian Politics?
-
Business6 months ago
Carrectly: Revolutionizing Car Care in Chicago
-
Business7 months ago
Saudi Arabia: Foreign Direct Investment Rises by 5.6% in Q1
-
Technology8 months ago
Comparing Apple Vision Pro and Meta Quest 3
-
Politics8 months ago
Indonesia and Malaysia Call for Israel’s Compliance with ICJ Ruling on Gaza Offensive
-
Technology8 months ago
Recent Developments in AI Ethics in America